A randomised, double blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in newly diagnosed patients with inoperable locally advanced NSCLC after definitive concurrent chemoradiation therapy

BI 1199.247

BI2017 – Identification of novel cancer antigens based on integration of different methods

Klinische Studie

Respect CVT

Studie Böhringer Ingelheim BI1399-0003 Balance